Skip to main content

Advertisement

SpringerLink
Log in

Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Our aim is to assess the prevalence and associated clinical features of anti-CCP (cyclic citrullinated peptide) antibodies for RF (rheumatoid factor)-positive and RF-negative rheumatoid arthritis (RA) and psoriatic arthritis (PsA). In a prospective, cross-sectional, multi-centre study, we determined the titres of anti-CCP antibodies in 208 RA patients (129 RF-positive, 79 RF-negative), 56 PsA patients and 39 healthy controls (HC). Clinical parameters including disease activity (disease activity score 28—DAS28), physical disability (health assessment questionnaire—HAQ), functional capacity (functional class) and radiological erosions were investigated in patients with RA. In PsA patients, clinical and radiological features were determined. Anti-CCP2 antibodies were measured using a second-generation anti-CCP enzyme-linked immunosorbent assay (Euro-Diagnostica, Netherlands). One-hundred four of 129 RF-positive RA (81%), 16 of 79 RF-negative RA (20%), seven of 56 PsA patients (12.5%) and none of the HC had anti-CCP antibodies. RA patients with anti-CCP antibodies had significantly higher disease activity, greater loss of function and more frequent erosive disease than anti-CCP antibody-negative group. In subgroup analysis, anti-CCP antibodies in RF-negative patients were also associated with erosive disease. All PsA patients with anti-CCP antibodies had symmetric arthritis with higher number of swollen joints. The prevalence of anti-CCP antibodies in RF-positive RA patients was significantly higher than in RF-negative RA and PsA patients. Anti-CCP antibodies were also associated with erosive disease in RF-negative RA patients. Both anti-CCP and RF tests were negative in 30% of the patients. Anti-CCP positivity was a frequent finding in PsA and associated with symmetrical polyarthritis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Vander Cruyssen B, Peene I, Cantaert T et al (2005) Anti-citrullinated protein/peptide antibodies (ACPA) in rheumatoid arthritis: specificity and relation with rheumatoid factor. Autoimmun Rev 4:768–774

    Google Scholar 

  2. van Boekel MAM, Vossenaar ER, van den Hoogen FHJ, van Venrooij WJ (2002) Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res Ther 4:87–93

    Google Scholar 

  3. Steiner G, Smolen J (2002) Autoantibodies in rheumatoid arthritis and their clinical significance. Arthritis Res Ther 4:S1–S5 (suppl 2)

    Google Scholar 

  4. Bas S, Perneger TV, Seitz M, Tiercy JM, Roux-Lombard P, Guerne PA (2002) Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology (Oxford) 41:809–814

    Article  CAS  Google Scholar 

  5. Kastbom A, Strandberg G, Lindroos A, Skogh T (2004) Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 63:1085–1089

    Article  PubMed  CAS  Google Scholar 

  6. Bas S, Genevay S, Meyer O, Gabay C (2003) Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford) 42:677–680

    Article  CAS  Google Scholar 

  7. Kroot EJA, de Jong BAW, van Leeuwen MA et al (2000) The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 43:1831–1835

    Article  PubMed  CAS  Google Scholar 

  8. Schellekens GA, Visser H, de Jong BAW et al (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43:155–163

    Article  PubMed  CAS  Google Scholar 

  9. Vencovsky J, Machacek S, Sedova L et al (2003) Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 62:427–430

    Article  PubMed  CAS  Google Scholar 

  10. Meyer O, Labarre C, Dougados M et al (2003) Anticitrullinated protein/peptide antibody assay in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 62:120–126

    Article  PubMed  CAS  Google Scholar 

  11. van Jaarsveld CH, ter Borg EJ, Jacobs JW et al (1999) The prognostic value of the antiperinuclear factor, anti-citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis. Clin Exp Rheumatol 17:689–697

    PubMed  Google Scholar 

  12. Jansen LMA, van Schaardenburg D, van der Horst-Bruinsma IE, van de Stadt RJ, de Koning MHMT, Dijkmans BAC. The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis. J Rheumatol 30:1691–1695

  13. Lee DM, Schur PH (2003) Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 62:870–874

    Article  PubMed  CAS  Google Scholar 

  14. Saraux A, Berthelot JM, Devauchelle V et al (2003) Value of antibodies to citrulline-containing peptides for diagnosing early rheumatoid arthritis. J Rheumatol 30:2535–2539

    PubMed  CAS  Google Scholar 

  15. Quinn MA, Gough AKS, Green MJ et al (2005) Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology (Oxford) Nov 15 (Epub ahead of print)

  16. Kamali S, Gurel-Polat N, Kasapoglu E et al (2005) Anti-CCP and anti-keratin antibodies in rheumatoid arthritis, primary Sjögren’s syndrome, and Wegener’s granulomatosis. Clin Rheumatol 24(6):673–676

    Article  PubMed  Google Scholar 

  17. Helliwell PS, Taylor WJ (2005) Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis 64:ii3–ii8 (suppl II)

    Article  PubMed  Google Scholar 

  18. Bogliolo L, Alpini C, Caporali R, Scire CA, Moratti R, Montecucco C (2005) Antibodies to cyclic citrullinated peptides in psoriatic arthritis. J Rheumatol 32:511–515

    PubMed  CAS  Google Scholar 

  19. Korendowych E, Owen P, Ravindran J, Carmichael C, McHugh N (2005) The clinical and genetic associations of anti-cyclic citrullinated peptide antibodies in psoriatic arthritis. Rheumatology (Oxford) 44(8):1056–1060

    Article  CAS  Google Scholar 

  20. Vander Cruyssen B, Hoffman IEA, Zmierczak H et al (2005) Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis 64:1145–1149

    Article  Google Scholar 

  21. Alenius GM, Berglin E, Rantapaa Dahlqvist S (2005) Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without manifestations of joint inflammation. Ann Rheum Dis Aug 11 (Epub ahead of print)

  22. Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324

    Article  PubMed  CAS  Google Scholar 

  23. Senerdem N, Gul A, Konice M et al (1999) The use of two different Health Assessment Questionnaires in Turkish rheumatoid arthritis population and assessment of the associations with disability. Clin Rheumatol 18:33–37

    Article  PubMed  CAS  Google Scholar 

  24. Bridges SL Jr (2001) Rheumatoid factor. In: Koopman WJ (ed) Arthritis and allied conditions. Williams and Wilkins, Philadelphia, pp 1223–1244

    Google Scholar 

  25. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ et al (2004) Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis. Arthritis Rheum 50:709–715

    Article  PubMed  Google Scholar 

  26. van Gaalen FA, van Aken J, Huizinga TWJ et al (2004) Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum 50:2113–2121

    Article  PubMed  Google Scholar 

  27. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW (2005) Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 7(5):R949–R958

    Article  PubMed  Google Scholar 

  28. De Rycke L, Peene I, Hoffman IEA et al (2004) Rheumatoid factor and anti-citrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extraarticular manifestations. Ann Rheum Dis 63:1587–1593

    Article  PubMed  Google Scholar 

  29. Goldbach-Mansky R, Lee J, McCoy A et al (2000) Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res Ther 2:236–243

    CAS  Google Scholar 

  30. Zeng X, Ai M, Tian X et al (2003) Diagnostic value of anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis. J Rheumatol 30:1451–1455

    PubMed  CAS  Google Scholar 

  31. McHugh NJ, Balachrishnan C, Jones SM (2003) Progression of peripheral joint disease in psoriatic arthritis: a 5 yr prospective study. Rheumatology (Oxford) 42:778–783

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Marmara, Istanbul, Turkey

    N. Inanc & H. Direskeneli

  2. Division of Hematology–Immunology, Department of Internal Medicine, Faculty of Medicine, University of Marmara, Istanbul, Turkey

    Y. Elbir

  3. Department of Internal Medicine, Uludağ University Medical School, Bursa, Turkey

    E. Dalkılıc

  4. Division of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey

    S. Kamalı, E. Kasapoglu-Günal & M. Inanc

  5. Fahrettin Kerim Gökay Cad. Gül AP. No: 168/13, 34730 Göztepe, Istanbul, Turkey

    N. Inanc

Authors
  1. N. Inanc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Dalkılıc
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Kamalı
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. Kasapoglu-Günal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Y. Elbir
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H. Direskeneli
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Inanc
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. Inanc.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Inanc, N., Dalkılıc, E., Kamalı, S. et al. Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol 26, 17–23 (2007). https://doi.org/10.1007/s10067-006-0214-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-006-0214-5

Keywords

Search

Navigation